About
Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator specifically indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF). It is typically prescribed for patients who have recently experienced a worsening heart failure event and are stabilized. The drug functions by directly stimulating sGC, an enzyme found in the cardiopulmonary system, which leads to an increase in intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP promotes smooth muscle relaxation, resulting in vasodilation and improved cardiac function, thereby reducing both cardiac preload and afterload.
The therapeutic action of vericiguat addresses the often-dysfunctional nitric oxide-sGC-cGMP pathway observed in chronic heart failure. By restoring and enhancing this critical signaling pathway, vericiguat helps to counteract the progressive nature of heart failure. Clinical trials have demonstrated its efficacy in improving clinical outcomes, significantly reducing the risk of cardiovascular death and hospitalization for heart failure in this vulnerable patient population. This makes vericiguat a valuable addition to the therapeutic arsenal for managing advanced HFrEF.
Uses
- Treatment of symptomatic chronic heart failure.
- For patients with reduced ejection fraction (HFrEF).
- Used after a recent worsening heart failure event.
- Reduces risk of cardiovascular death and heart failure hospitalization.
Directions For Use
Take once daily with food. Do not crush or chew tablets.
Benefits
- Reduces risk of cardiovascular death.
- Decreases heart failure hospitalizations.
- Improves cardiac function.
- Novel mechanism of action for heart failure.
- Oral, once-daily administration.
- Targets a key pathway in heart failure progression.
Side Effects
- Hypotension (low blood pressure)
- Anemia
- Dizziness
- Nausea
- Headache
- Fatigue
- Dyspepsia
- Peripheral edema
- Syncope
- Vomiting
- Diarrhea
- Increased liver enzymes
Safety Measures
- Alcohol - Use with caution as alcohol can exacerbate hypotension, a common side effect of vericiguat.
- Pregnancy - Contraindicated in pregnancy due to potential for embryo-fetal toxicity. Women of childbearing potential must use effective contraception.
- Breastfeeding - Not recommended during breastfeeding due to potential for serious adverse reactions in the infant.
- Liver - Use with caution in patients with moderate hepatic impairment; not studied in severe impairment.
- Kidney - Use with caution in patients with severe renal impairment (eGFR <15 mL/min/1.73 m²) or on dialysis.
- Lung - Generally safe, but caution in patients with severe pulmonary hypertension not related to heart failure.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!